A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - ND

• Conditions: Parkinson disease; MedDRA version: 6.1Level: PTClassification code 10061536

• Registration Number: EUCTR2005-005423-34-IT
• Lead Sponsor: GlaxoSmithKline R D

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10-03
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 516

Inclusion Criteria

1.Men or non-pregnant/non-breast-feeding women of at least 30 years of age at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception during the study and for at least one month prior to randomisation and one month following completion of the study. Acceptable contraceptive methods include oral contraception, surgical sterilization, intrauterine device IUD , or diaphragm IN ADDITION to spermicidal foam and condom on male partner, or systemic contraception i.e. Norplant System . 2.Diagnosis of idiopathic Parkinson s disease according to modified Hoehn Yahr criteria Stages II-IV and demonstrating lack of control with L-dopa therapy e.g. end of dose akinesia, simple on / off fluctuations . 3.Subjects receiving a stable dose of L-dopa for at least 4 weeks prior to Baseline Period. 4.Subjects provided written informed consent for the study. 5.A minimum of 3 hours awake time off for each diary day was recorded during the Baseline Period. 6.Subjects are willing and able to comply with study procedures, including diary card completion and follow-up clinic visits.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Late stage advanced subjects demonstrating incapacitating dyskinesias on their stable dose of L-dopa. 2.Presence, or history within the previous 3 months, of significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological other than Parkinson s disease , or cardiovascular disease or active malignancy other than basal cell cancer . 3.Any abnormality, at screening, that the investigator deems to be clinically relevant on history, physical examination and in diagnostic laboratory tests including ECG. 4.Recent history of severe dizziness or fainting due to postural hypotension on standing. 5.Clinical dementia that in the judgment of the investigator would preclude assessment of the subject. 6.Subjects with neurotic behaviour, crippling degenerative arthritis or limb amputations, which would preclude efficacy or safety assessments. 7.Subjects with prior or current major psychosis e.g. schizophrenia or psychotic depression e.g., scoring 3 or 4 on UPDRS item 2 thought disorder or item 3 depression . 8.Recent history or current evidence of drug abuse or alcoholism. 9.Consumption of any dopamine agonist within 4 weeks of the screening visit. 10.Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole or to drugs with a similar chemical structure that would preclude long-term dosing with ropinirole IR or PR/XR tablets. 11.Withdrawal, introduction, or change in dose of HRT and/or any drug known to substantially inhibit Cytochrome P 450 1A2 CYP1A2 e.g. ciprofloxacin, fluvoxamine, cimetidine, ethinyloestradiol or induce CYP1A2 e.g. tobacco, omeprazole within 7 days prior to enrolment. Subjects already on chronic therapy with any of these agents may be enrolled but must remain on stable doses of the agent from 7 days prior to enrolment through the end of the Treatment Period. 12.Use of an investigational drug from 30 days prior to enrolment through to the end of the Treatment Period. 13.More than 12 hours off time recorded on any individual day during the Baseline Period.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To demonstrate the superiority of ropinirole PR/XR tablets over ropinirole IR tablets when used as adjunctive therapy to L-dopa in subjects with advanced staged Parkinson s disease who are not adequately controlled on L-dopa;Secondary Objective: To evaluate the efficacy profile of ropinirole PR/XR tablets compared with ropinirole IR tablets as adjunctive therapy to L-dopa in subjects with Parkinson s disease. To evaluate the safety profile of ropinirole PR/XR and IR tablets as adjunctive therapy to L-dopa in subjects with Parkinson s disease.;Primary end point(s): Percent of subjects with at least a 20 maintained reduction in time off at endpoint - this is defined as the percent of subjects with at least a 20 reduction from baseline in time off at endpoint Week 24 LOCF and the timepoint immediately preceding this endpoint . The general definition of time off includes a lack of mobility bradykinesia with or without additional features such as tremor or rigidity.